Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2026
Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083
Raphael J Landovitz, Jessica M Fogel, Fei Gao, et al.
The Lancet. HIV
|
October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
The Lancet. HIV
|
October 2, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
Mark A Marzinke, Brett Hanscom, Zhe Wang, et al.
The Journal of Infectious Diseases
|
March 19, 2021
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
The Journal of Infectious Diseases
|
March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084
Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
BMC Immunology
|
February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Lancet (London, England)
|
April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Sinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
Journal of the International AIDS Society
|
October 24, 2018
Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis
Kathryn E Lancaster, Irving F Hoffman, Brett Hanscom, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2026
Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083
Raphael J Landovitz, Jessica M Fogel, Fei Gao, et al.
The Lancet. HIV
|
October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
The Lancet. HIV
|
October 2, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
Mark A Marzinke, Brett Hanscom, Zhe Wang, et al.
The Journal of Infectious Diseases
|
March 19, 2021
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
The Journal of Infectious Diseases
|
March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084
Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
BMC Immunology
|
February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Lancet (London, England)
|
April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Sinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
Journal of the International AIDS Society
|
October 24, 2018
Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis
Kathryn E Lancaster, Irving F Hoffman, Brett Hanscom, et al.
Page
of 8